Is CBG (cannabigerol) one of the next big trends in the Cannabis space? Breeder’s Best thinks so!  Recently our Medical Director Ethan Russo, MD, spearheaded a first of its kind patient survey querying people who use CBG-predominant Cannabis or cannabis products.  The results were fascinating.

See the attached poster presented at the 2021 International Cannabinoid Research Society Symposium, the most important Cannabis science conference. 

Respondents reported using CBG most successfully for addressing symptoms of anxiety, chronic pain, depression and insomnia. Unlike THC, CBG is a non-intoxicating cannabinoid, which is attractive to a large part of the population.  Also, CBG has a benign adverse event profile and limited-to-no withdrawal symptoms.  Patients reported their conditions to be “very much improved” or “improved” with CBG predominant Cannabis flower or preparations.

Popularity of CBG-rich Cannabis (hemp and otherwise) is taking off in the Pacific Northwest.  We predict the popularity of this effective and versatile molecule will increase rapidly stimulating innovation and demand for CBG-rich flower and products. Much like what we saw with the CBD craze, it is likely that growers and manufacturers may find it hard to meet market demands until diverse CBG-rich genetics become widely available.

Our first CBG-rich offering is for a hemp variety our breeder has aptly named ‘Anomaly’. Exclusively available through Breeder’s Best and its agents, ‘Anomaly’ boasts 11-15% CBG and 2.8-3.6% terpenes. ‘Anomaly’ has been confirmed to carry a double-mutant in the main synthesis pathways of both THC and CBD, explaining the consistent near-zero levels of THC and CBD. Access to unique and rare genetics like ‘Anomaly’, will become increasingly important as CBG products start to gain popularity in the marketplace.

In addition to popularity in the consumer market we fully expect CBG will be included in a variety of pharmaceutical preparations to treat certain cancers and other chronic illness. The survey by Russo et al,  indicates CBG-based medicines can be safely used in human randomized clinical trials. 

Also included on the research team are Carrie Cutler, PhD; Amanda Stueber; Breeder’s Best VP of Marketing and Business Development Nishi Whiteley; and Michelle Sexton, ND.